At a glance
ClinicalIndex Comparison RecordPhase 3Completed· 29 enrolled
Drug / intervention
OBI-1biological
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
Efficacy and Safety of B-Domain Deleted Recombinant Porcine Factor VIII (OBI-1) in the Treatment of Acquired Hemophilia A Due to Factor VIII Inhibitory Auto-antibodies
In Brief
A Phase 3 clinical trial evaluating OBI-1 for Acquired Hemophilia A. Completed, enrolled 29 participants across 12 sites in 4 countries.
Detailed Summary
This study is to test whether the study drug (OBI-1) is safe and effective for the treatment of serious bleeding episodes in people with acquired hemophilia A.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsAcquired Hemophilia A
CountriesCanada, India, United Kingdom, United States
Collaborators--
Timeline
Phase 3CompletedFinished
2011201220132014201520162017201820192020202120222023202420252026
First PostedAug 2010
Enrollment StartNov 2010
Primary CompletionJul 2013
Study CompletionOct 2013
TodayJul 2026
First PostedAug 10, 2010
Enrollment StartNov 10, 2010
Primary CompletionJul 1, 2013
Study CompletionOct 9, 2013
TodayJul 2, 2026
Enrollment to primary: 2.6 yearsPosted 15.9 years ago
Interventions
OBI-1biological
Intravenous infusion